BharatReddyMocherlaMD

Nuclear Medicine • Las Vegas, NV

Physician

Join to view full profile

Are you Dr. Mocherla?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 17 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
7320 Bachelors Button Dr
Las Vegas, NV 89131
Phone+1 646-291-7929

Fax+1 702-432-4005

Summary

Dr. Bharat Mocherla, MD is a board certified nuclear medicine physician in Las Vegas, Nevada. He is currently licensed to practice medicine in Nevada, Delaware, and Michigan.

Education & Training

Icahn School of Medicine at Mount SinaiResidency, Nuclear Medicine, 2006 - 2008
Stony Brook Medicine/University HospitalInternship, Internal Medicine, 2005 - 2006
Siddhartha Medical College NTRClass of 2003

Certifications & Licensure

CA State Medical License 2008 - 2026
DE State Medical License 2022 - 2025
MI State Medical License 2022 - 2025
NM State Medical License 2015 - 2025
NV State Medical License 2009 - 2025
AZ State Medical License 2013 - 2018
OH State Medical License 2016 - 2018
WA State Medical License 2014 - 2017
American Board of Nuclear Medicine Nuclear Medicine
Join now to see all

Clinical Trials

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
18F-AV-1451 Autopsy Study Start of enrollment: 2015 Sep 01
Completed
Phase 3
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

10 citations
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Teresa H Evering, Kara W Chew, Mark J Giganti, Carlee Moser, Mauricio Pinilla
Annals of Internal Medicine. 2023-05-01
17 citations
A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic...
Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L. Gottlieb, Peter Chen
Clinical Infectious Diseases. 2021-10-28
662 citations
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb, Ajay Nirula, Peter Chen, Joseph Boscia, Barry Heller
JAMA. 2021-02-16

Press Mentions

Las Vegas Medical Research Center Participates in NIH’s ACTIV-2 in Quest for Early Onset COVID-19 TherapeuticsApril 7th, 2021
Las Vegas Doctors Test COVID-19 Treatments for Patients Recovering at HomeApril 5th, 2021